Estimate likelihood of bone marrow involvement in Hodgkin's lymphoma.
Although bone marrow involvement is generally rare in Hodgkin’s lymphoma (4-14% of patients), the demonstration of involvement has prognostic and therapeutic implications. This clinical prediction rule identifies patients with low, standard, or high-risk for BM involvement. Physicians should make their own decision as to whether a bone marrow biopsy should be completed for each individual patient based on the referral pattern to their hospital and the treatment strategies applied. In the study reported below, one option suggested by the authors would be to avoid staging BM biopsies in patients in the “low-risk” group, offer a unilateral biopsy in standard-risk patients, and pursue bilateral biopsies in high-risk patients. However, this approach has not been prospectively validated.
Vassilakopoulos et al.
Although bone marrow involvement is generally rare in Hodgkin’s lymphoma (4-14% of patients), the demonstration of involvement has prognostic and therapeutic implications. This clinical prediction rule identifies patients with low, standard, or high-risk for BM involvement. Physicians should make their own decision as to whether a bone marrow biopsy should be completed for each individual patient based on the referral pattern to their hospital and the treatment strategies applied. In the study reported below, one option suggested by the authors would be to avoid staging BM biopsies in patients in the “low-risk” group, offer a unilateral biopsy in standard-risk patients, and pursue bilateral biopsies in high-risk patients. However, this approach has not been prospectively validated.
Vassilakopoulos et al.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
